Bayer AG has experienced a volatile range of events, with significant upticks and major downward spirals. The biotech behemoth's shares have seen an impressive surge following its substantial legal victories against Roundup cancer claims in the US. This allows for positive financial speculation despite a tumultuous past, with the company experiencing its biggest daily gain since 2009. However, it has also encountered significant losses in the past five years, one of the significant ones being a 48% loss for shareholders.
A major factor contributing to its downturn was the blow dealt by the termination of the Asundexian trial and a $1.5bn Roundup verdict, which led to Bayer's worst day ever, with stocks sinking to a decade's worth low. In another instance, shares experienced a drastic drop following a negative trial result and a court loss related to their Roundup case.
Questions about Bayer's financial management emerge as it battles large-scale debts. To tackle its burgeoning debt burden, Bayer announced a drastic dividend cut, a move which further led to a fall in shares. Amid these financial tribulations, Bayer appears to be buoyed by their robust sports team, which continues to thrive and solid performance from their Crop Science unit.
BAYER Stocks News Analytics from Fri, 27 Oct 2023 07:00:00 GMT to Fri, 16 Aug 2024 14:48:27 GMT - Rating 2 - Innovation -4 - Information 2 - Rumor -3